A new antiinflammatory compound, leumedin, inhibits modification of low density lipoprotein and the resulting monocyte transmigration into the subendothelial space of cocultures of human aortic wall cells

The Journal of Clinical Investigation
M NavabA M Fogelman

Abstract

Addition of leumedin, N-[9H-(2,7-dimethylfluorenyl-9-methoxy) carbon]-L-leucine at 30-60 microM together with LDL almost completely prevented the induction of monocyte chemotactic protein mRNA, reduced monocyte chemotactic protein 1 levels by 84%, and inhibited monocyte migration into the subendothelial space of cocultures of human aortic wall cells by < or = 98%. LDL incubated with leumedin formed a stable complex that remained intact even after refloating in an ultracentrifuge. Leumedin at 50 microM did not change conjugated diene formation during coculture modification of LDL or Cu++ catalyzed oxidation of LDL. Unlike LDL from control rabbits, LDL isolated from rabbits that were injected with 20 mg/kg leumedin was remarkably resistant to modification by the coculture and did not induce monocyte migration to a significant degree. Moreover, HDL isolated from rabbits injected with leumedin was far more effective in protecting against LDL modification by the artery wall cocultures than HDL from control rabbits. We conclude that leumedins can associate with lipoproteins in vivo, rendering LDL resistant to biological modification and markedly amplifying the protective capacity of HDL against in vitro LDL oxidation by artery wall c...Continue Reading

References

Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S D CushingA M Fogelman
Dec 1, 1991·The Journal of Clinical Investigation·J L Witztum, D Steinberg
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·R M BurchC Ko
Sep 1, 1991·Circulation·D Steinberg
Jul 9, 1991·European Journal of Pharmacology·L Noronha-BlobR M Burch
Jun 1, 1991·The Journal of Clinical Investigation·F LiaoA M Fogelman
Jan 1, 1990·Free Radical Research Communications·B Halliwell
Apr 1, 1990·The Journal of Clinical Investigation·J A BerlinerA M Fogelman
May 1, 1989·The Journal of Experimental Medicine·S K LoS D Wright
Apr 6, 1989·The New England Journal of Medicine·D SteinbergJ L Witztum
Jul 25, 1988·The American Journal of Cardiology·G M Chisolm, D W Morel
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T KitaC Kawai
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Dec 16, 2006·Current Atherosclerosis Reports·Benjamin J AnsellAlan M Fogelman
Feb 1, 1997·In Vitro Cellular & Developmental Biology. Animal·F KinardY J Schneider
Sep 1, 1997·The Journal of Clinical Investigation·K IshikawaA J Lusis
Dec 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·P ReavenJ Barnett
Nov 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·P MataM de Oya
Oct 16, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·M TakakuT Kodama
Jan 29, 2021·Lab on a Chip·Vahid HosseiniAli Khademhosseini

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.